Cargando…
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression
Bladder cancer (BC) is a heterogeneous disease with highly variable clinical and pathological features, and resulting in different outcomes. Such heterogeneity ensues from distinct pathogenetic mechanisms and may consistently affect treatment responses in single patients. Thus, over the last few yea...
Autores principales: | Sanguedolce, Francesca, Zanelli, Magda, Palicelli, Andrea, Ascani, Stefano, Zizzo, Maurizio, Cocco, Giorgia, Björnebo, Lars, Lantz, Anna, Falagario, Ugo Giovanni, Cormio, Luigi, Carrieri, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319819/ https://www.ncbi.nlm.nih.gov/pubmed/35887164 http://dx.doi.org/10.3390/ijms23147819 |
Ejemplares similares
-
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation
por: Sanguedolce, Francesca, et al.
Publicado: (2022) -
Clinicopathological Features and Survival Analysis in Molecular Subtypes of Muscle-Invasive Bladder Cancer
por: Sanguedolce, Francesca, et al.
Publicado: (2023) -
HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role
por: Sanguedolce, Francesca, et al.
Publicado: (2023) -
Distinctive morphological and molecular features of urothelial carcinoma with an inverted growth pattern
por: Sanguedolce, Francesca, et al.
Publicado: (2021) -
Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls
por: Zanelli, Magda, et al.
Publicado: (2022)